Phosphate control in reducing FGF23 levels in hemodialysis patients

被引:30
|
作者
Rodelo-Haad, Cristian [1 ,2 ,3 ]
Rodriguez-Ortiz, Maria E. [1 ,3 ]
Martin-Malo, Alejandro [1 ,2 ,3 ]
Victoria Pendon-Ruiz de Mier, M. [1 ,2 ,3 ]
Luisa Aguera, M. [1 ,2 ,3 ]
Munoz-Castaneda, Juan R. [1 ,2 ,3 ]
Soriano, Sagrario [1 ,2 ,3 ]
Caravaca, Francisco [4 ]
Antonia Alvarez-Lara, M. [1 ,2 ,3 ]
Felsenfeld, Arnold [5 ,6 ]
Aljama, Pedro [1 ,2 ,3 ]
Rodrigue, Mariano [1 ,2 ,3 ]
机构
[1] Univ Cordoba, Inst Maimonides Invest Biomed Cordoba IMIBIC, Reina Sofia Univ Hosp, Cordoba, Spain
[2] Reina Sofia Univ Hosp, Nephrol Serv, Cordoba, Spain
[3] RETICs REDinREN Natl Inst Hlth Carlos III, Madrid, Spain
[4] Infanta Cristina Hosp, Nephrol Serv, Badajoz, Spain
[5] UCLA, Wadsworth VA, Dept Med, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA
[6] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
来源
PLOS ONE | 2018年 / 13卷 / 08期
关键词
GROWTH-FACTOR; 23; CHRONIC KIDNEY-DISEASE; LEFT-VENTRICULAR HYPERTROPHY; CKD-MBD; SECONDARY HYPERPARATHYROIDISM; CARDIOVASCULAR-DISEASE; MINERAL METABOLISM; DIALYSIS PATIENTS; LANTHANUM CARBONATE; PARATHYROID-HORMONE;
D O I
10.1371/journal.pone.0201537
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background In hemodialysis patients, high levels of Fibroblast Growth Factor 23 (FGF23) predict mortality. Our study was designed to test whether the control of serum phosphate is associated with a reduction in serum FGF23 levels. Additionally other variables with a potential effect on FGF23 levels were evaluated. Material and methods The effect of sustained (40-weeks) control of serum phosphate on FGF23 levels (intact and c-terminal) was evaluated in 21 stable hemodialysis patients that were not receiving calcimimetics or active vitamin D. Patients received non-calcium phosphate binders to maintain serum phosphate below 4.5 mg/dl. In an additional analysis, values of intact-FGF23 (iFGF23) and c-terminal FGF23 (cFGF23) from 150 hemodialysis patients were correlated with parameters of mineral metabolism and inflammation. Linear mixed models and linear regression were performed to evaluate longitudinal trajectories of variables and the association between FGF23 and the other variables examined. Results During the 40-week treatment, 12 of 21 patients achieved the target of serum phosphate <4.5 mg/dl. In these 12 patients, iFGF23 decreased to less than half whereas cFGF23 did not reduce significantly. In patients with serum phosphate >4.5 mg, iFGF23 and cFGF23 increased two and four-fold respectively as compared with baseline. Furthermore, changes in serum phosphate correlated with changes in C-reactive protein (hs-CRP). In our 150 hemodialysis patients, those in the higher tertile of serum phosphate also showed increased hs-CRP, iPTH, iFGF23 and cFGF23. Multiple regression analysis revealed that iFGF23 levels directly correlated with both serum phosphate and calcium, whereas cFGF23 correlated with serum phosphate and hs-CRP but not with calcium. Conclusions The control of serum phosphate reduced iFGF23. This reduction was also associated with a decreased in inflammatory parameters. Considering the entire cohort of hemodialysis patients, iFGF23 levels correlated directly with serum phosphate levels and also correlated inversely with serum calcium concentration. The levels of cFGF23 were closely related to serum phosphate and parameters of inflammation.
引用
收藏
页数:23
相关论文
共 50 条
  • [31] Fibroblast growth factor 23 (FGF23) level is associated with ultrafiltration rate in patients on hemodialysis
    Nishizawa, Yoko
    Hosoda, Yumi
    Horimoto, Ai
    Omae, Kiyotsugu
    Ito, Kyoko
    Higuchi, Chieko
    Sakura, Hiroshi
    Nitta, Kosaku
    Ogawa, Tetsuya
    HEART AND VESSELS, 2021, 36 (03) : 414 - 423
  • [32] Fibroblast growth factor 23 (FGF23) level is associated with ultrafiltration rate in patients on hemodialysis
    Yoko Nishizawa
    Yumi Hosoda
    Ai Horimoto
    Kiyotsugu Omae
    Kyoko Ito
    Chieko Higuchi
    Hiroshi Sakura
    Kosaku Nitta
    Tetsuya Ogawa
    Heart and Vessels, 2021, 36 : 414 - 423
  • [33] BASELINE LEVELS OF FGF23 AND EFFECTS OF ETELCALCETIDE
    Vervloet, M.
    Cooper, K.
    Block, G.
    Chertow, G.
    Fouqueray, B.
    Moe, S.
    Sun, Y.
    Tomlin, H.
    Wolf, M.
    Oberbauer, R.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2018, 33
  • [34] FGF23 and Phosphate-Cardiovascular Toxins in CKD
    Vogt, Isabel
    Haffner, Dieter
    Leifheit-Nestler, Maren
    TOXINS, 2019, 11 (11)
  • [35] Phosphate and FGF23 in the renoprotective benefit of RAAS inhibition
    de Seigneux, Sophie
    Martin, Pierre-Yves
    PHARMACOLOGICAL RESEARCH, 2016, 106 : 87 - 91
  • [36] Controlled dietary phosphate loading in healthy young men elevates plasma phosphate and FGF23 levels
    Gerber, Jennifer Scotti
    Arroyo, Eva Maria Pastor
    Pastor, Johanne
    Correia, Miguel
    Rudloff, Stefan
    Moe, Orson W.
    Egli-Spichtig, Daniela
    Mohebbi, Nilufar
    Wagner, Carsten A.
    PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY, 2025, 477 (03): : 495 - 508
  • [37] Molecular interactions of FGF23 and PTH in phosphate regulation
    Lanske, Beate
    Razzaque, Mohammed S.
    KIDNEY INTERNATIONAL, 2014, 86 (06) : 1071 - 1074
  • [38] FGF23 at the crossroads of phosphate, iron economy and erythropoiesis
    Daniel Edmonston
    Myles Wolf
    Nature Reviews Nephrology, 2020, 16 : 7 - 19
  • [39] Role of FGF23 in phosphate homeostasis and related disorders
    Fukumoto, S.
    CALCIFIED TISSUE INTERNATIONAL, 2008, 82 : S23 - S23
  • [40] FGF23 AND SYNDROMES OF ABNORMAL RENAL PHOSPHATE HANDLING
    Bergwitz, Clemens
    Jueppner, Harald
    ENDOCRINE FGFS AND KLOTHOS, 2012, 728 : 41 - 64